Wall Street equity research consensus ratings for Foghorn Therapeutics predominantly lean toward a buy or strong buy classification, driven by enthusiasm for its proprietary chromatin-regulatory drug discovery engine. However, individual investor recommendations depend on risk tolerance, given the inherent clinical-stage biotechnology volatility and drug development timelines.